¶µ¼ø ²¼ÅÄ¡¡¾­Ç·
¡Ê¹ÖºÂôÅö¶µ¼ø¡Ë ¶µ¼ø¼Ì¿¿
¹Ö»Õ

±óÆ£¡¡ÂÙɧ¡ÊÉٻλÔΩÃæ±ûɱ¡¤Ø½Ð¸þ¡Ë

¼¯¡¡ÃÒ·Ã

¾®Ê÷¡¡Â¿²í¡Ê¸üÌÚ»ÔΩɱ¡¤Ø½Ð¸þ¡Ë

½õ¶µ

×¢²¬¡¡¿®°ì¡Ê¾ïÈ×ɱ¡¤Ø½Ð¸þ¡Ë
ÅÚ°æ¡¡µªµ±¡ÊµÙ¿¦¡Ë
µÆÃÏ¡¡Î¼
À¾Â¼¡¡Í¥´ð
±­»ô¡¡¤Ê¤Ä¤³

Âç³Ø±¡

µ×ÊÝÅÄ¡¡À±Êâ
Âçë¡¡Íýλ

ɱ¡ÉÂÍýÉô
¡Ê½Ð¸þ¡Ë

Éí°É±¡

¿ÇÎÅÉôĹ

²¼ÅÄ¡¡¾­Ç·¡Ê¶µ¼ø¡Ë

¿ÇÎÅÉûÉôĹ

Â붶¡¡¹À¹¬¡Ê¶µ¼ø¡Ë

¿ÇÎÅ°åĹ

À¶Àî¡¡µ®»Ò¡Ê¶µ¼ø¡Ë

¿ÇÎÅ°å°÷

º´Æ£¡¡½Ô¡Ê¹Ö»Õ¡Ë

¿¼ß·¡¡Ç«¡Ê½õ¶µ¡Ë

²ÏÆâ¡¡¹á¹¾¡Ê½õ¶µ¡Ë

Á°ÅÄ¡¡Ì¤Íè¡Ê½õ¶µ¡Ë

½Ú¿ÇÎÅ°å°÷

ËÜ´Ö¡¡»Ö¸ù¡Ê½õ¶µ¡Ë

¾®ÎÓ¡¡¸­»Ê¡Ê½õ¶µ¡Ë

¥ì¥¸¥Ç¥ó¥È

¸Þ̣߷¡¡°ìδ¡Ê½õ¶µ¡Ë
º´ÃÝ¡¡¿¿Íý¡Ê½õ¶µ¡Ë
´äÆâ¡¡Íõ¡Ê½õ¶µ¡Ë
ÅÄùõ¡¡°¼»Ò¡Ê½õ¶µ¡Ë
µ®²È¡¡¸ùÊå¡Ê½õ¶µ¡Ë

³ë¾þ°åÎÅ¥»¥ó¥¿¡¼

¿ÇÎÅÉôĹ

Ì¡¹À°ì¡Ê½Ú¶µ¼ø¡Ë

Î×¾²ÀìǤ¶µ¼ø

ÃӾ塡²íÇî

¿ÇÎÅ°å°÷

¾¾ß·¡¡½Õ²Ú¡Ê½õ¶µ¡Ë

Â軰ɱ¡

¿ÇÎÅÉôĹ

¸¶ÅÄ¡¡Å°¡Ê½Ú¶µ¼ø¡Ë

¿ÇÎÅ°å°÷

Ã漡¡Ëãͽ¡Ê½õ¶µ¡Ë

ÌÚ¼¡¡´²»Ò¡Ê½õ¶µ¡Ë

¥ì¥¸¥Ç¥ó¥È¡¡

²Ï¸¶¡¡¹ª¹É¡Ê½õ¶µ¡Ë

Çðɱ¡

¿ÇÎÅÉôĹÂå¹Ô

´äËÜ¡¡²íÈþ¡Ê½õ¶µ¡Ë

¿ÇÎÅ°å°÷

»°Âð¡¡Èþº´Âå¡Ê½õ¶µ¡Ë
ºä¸ý¡¡Îûҡʽõ¶µ¡Ë

½Ú¿ÇÎÅ°å°÷

ȾÅÄ¡¡¾Í»Ò¡Ê½õ¶µ¡Ë

¹ÖºÂ¡Ê¸¦µæ¼¼¡Ë¤Î³µÍ×
¡¡

¡¡ÉÂÍý³Ø¤Î¹ÖµÁ¤Ï¡¢ËܳؤÎÁÏΩ¤Îǯ¤ËÅö¤¿¤ëÀ®°å²ñ¹Ö½¬½ê³«ÀߤÎÌÀ¼£14ǯ5·î1Æü¤ËÃÙ¤ì¤ë¤³¤È1ǯ¤Ë¤·¤Æ¤Ê¤µ¤ì¤Æ¤ª¤ê¡¢ÅöÉÂÍý³Ø¹ÖºÂ¤Î¸»Î®¤ò¤³¤³¤Þ¤ÇÁ̤뤳¤È¤¬½ÐÍè¤Þ¤¹¡£½éÂåÉÂÍý³Ø¶µ¼ø¤ÏÌÀ¼£43ǯ¤Ë½¢Ç¤¤·¤¿º£Íµ»á¤Ç¤¢¤ë¡Ê¸å¤ËË̳¤Æ»Âç³Ø¤ËžǤ¡Ë¡£°Ê¸åÌÚ¼ůÆó¡¢Âç¾ì¾¡Íø¡¢¹âÌÚʸ°ì¡¢ÀÐÀî±ÉÀ¤¡¢¾¾ËÜÉð»ÍϺ¡¢ÍõÂôÌÐͺ¡¢µí¹þ¿·°ìϺ¡¢±©Ìî´²¡¢ÃÓ¾å²íÇî¤Î³Æ»á¤¬¶µ¼ø¤Ë½¢Ç¤¡¢¸½ºß¤Î²¼Åľ­Ç·¤Ë°ú¤­·Ñ¤¬¤ì¤Æ¤¤¤Þ¤¹¡£
¡¡¸¦µæ¤ÏÅÁÅýŪ¤Ë¿ÍÂÎÉÂÍý³Ø¡Ê¡´ïÉÂÍý³Ø¡¢³°²ÊÉÂÍý³Ø¡¢¼ðáçÉÂÍý³Ø¡Ë¤òÃæ¿´¤ËÉý¹­¤¯¹Ô¤Ê¤Ã¤Æ¤­¤Æ¤ª¤ê¡¢¶áǯ¼Â¸³ÉÂÍý³Ø¤âƳÆþ¤·¤Æ¤ª¤ê¤Þ¤¹¡£ÉÂÍý³Ø¤Ï¼þÃΤΤ褦¤Ë¼À´µ¤Î¸¶°ø¤¢¤ë¤¤¤ÏÀ®¤êΩ¤Á¤ÎµæÌÀ¤ò¼çÌÜŪ¤È¤¹¤ë³ØÌäÎΰè¤Ç¡¢ÅÁÅýŪ¤Ë˶¸¡¤Ë¾Ýħ¤µ¤ì¤ë¤è¤¦¤Ë·ÁÂֳؤ¬ÊýË¡ÏÀ¤È¤·¤ÆÍѤ¤¤é¤ì¤Æ¤­¤Æ¤ª¤ê¤Þ¤¹¡£½¾¤Ã¤ÆÉÂÍý³Ø¤òÀ칶¤¹¤ë¤â¤Î¤Ï¡¢ÉÂÍý·ÁÂֳؤȤϲ¿¤«¤È¤¤¤¦¤³¤È¤ò¹Í¤¨¡¢·ÁÂÖ³ØŪ¤Ê¤â¤Î¤Î¸«Êý¤ËÀºÄ̤¹¤ë¤è¤¦ÅØÎϤ·¤Ê¤±¤ì¤Ð¤Ê¤é¤Ê¤¤¤³¤È¤Ï¸À¤¦¤Þ¤Ç¤â¤¢¤ê¤Þ¤»¤ó¡£¤½¤Î¾å¤Ç¶áǯÃø¤·¤¯È¯Ã£¤·¤Æ¤¤¤ë¼ï¡¹¤Î¼êË¡¡¢Î㤨¤ÐÁ°½Ò¤Î¼Â¸³ÉÂÍý³ØŪ¼êË¡¤òƳÆþ¤·¡¢·ÁÂֳؤò´ðÈפȤ·¤¿³ØÌä¤ò¹¹¤ËȯŸ¤µ¤»¤ë¤Ù¤­¤Ç¤¢¤ë¤È¹Í¤¨¤Æ¤¤¤Þ¤¹¡£
¡¡¥¹¥¿¥Ã¥Õ¤Ï¶µ°é¡¢¸¦µæ¤Ë½¾»ö¤·¤Ä¤Ä¡¢É±¡ÉÂÍýÉô¤Î¶È̳¤Ë¤â·È¤ï¤Ã¤Æ¤¤¤Þ¤¹¡£°ø¤ß¤Ëɱ¡ÉÂÍýÉô¤ÏÊ¿À®8ǯ4·î¤Ëɱ¡¡ÊËܱ¡¡¢Ê¬±¡¡Ë¤ËÀßÃÖ¤µ¤ì˶¸¡¡¢À¸¸¡¡¢ºÙ˦¿Ç¶È̳¤ò¹Ô¤Ê¤Ã¤Æ¤ª¤ê¡¢¥¹¥¿¥Ã¥Õ¤ÏÁ´°÷¹ÖºÂ¤«¤é¤Î½Ð¸þ¤ÎÂÎÀ©¤ò¤È¤Ã¤Æ¤ª¤ê¤Þ¤¹¡£¸½ºßÀ¸¸¡¿ôǯ´ÖÌó16,000·ï¡¢ºÙ˦¿Ç¿ôÌó17,000·ï¤Ë¤Î¤Ü¤ê¡¢¿ÇÃǤÎÀµ³ÎÀ­¡¢¿×®À­¤ò¥â¥Ã¥È¡¼¤Ëɱ¡¿ÇÎŤËÂ礤¤Ë¹×¸¥¤·¤Æ¤¤¤Þ¤¹¡£Ë¶¸¡¤Ïǯ´Ö40¡Á50ÂΤǡ¢¸º¾¯·¹¸þ¤Ë¤¢¤ê¤Þ¤¹¤¬¡¢¿ÇÎŤμÁ¤ò΢ÂǤÁ¤¹¤ë½ÅÍפʥХí¥á¡¼¥¿¡¼¤È¤â¸À¤ï¤ì¤Æ¤ª¤ê¡¢¶ËÎÏÎ×¾²¤Ø¤Î¥Õ¥£¡¼¥É¥Ð¥Ã¥¯¤ËÅؤá¤Æ¤¤¤Þ¤¹¡£ ÉÂÍý³Ø¹ÖºÂ¤Èɱ¡ÉÂÍýÉô¤Ï¡¢¶µ°é¡¢¿ÇÎŤ˹׸¥¤·¤Ä¤Ä¡¢¼«Í³¤ÊÊ·°Ïµ¤¤ÎÃæ¤ÇÆä˿ÍÂΡ¦¼Â¸³ÉÂÍý³Ø¤ËÎϤòÆþ¤ì¸¦µæ¤ò¿Ê¤á¤Æ¤ª¤ê¤Þ¤¹¡£

¢¥ ¤³¤Î¥Ú¡¼¥¸¤Î¥È¥Ã¥×¤Ø
ÉÂÍýÀìÌç°å
¡¡

¡¡ÉÂÍýÀìÌç°å¤Ï3ǯ´Ö¤ÎÉÂÍý¸¦½¤¤Î¸å¡¢ÆüËÜÉÂÍý³Ø²ñ¤Î»Ü¹Ô¤¹¤ë»î¸³¤ò¤¦¤±¡¢¹ç³Ê¤¹¤ì¤ÐÆüËÜÉÂÍý³Ø²ñ¤ÎǧÄꤹ¤ëÉÂÍýÀìÌç°å¤Ë¤Ê¤ë¤³¤È¤¬½ÐÍè¤Þ¤¹¡£¼õ¸³»ñ³Ê¤Ë¤Ï¡¢½é´üÎ×¾²¸¦½¤¤ò½ªÎ»¤·¤Æ¤¤¤ë¤³¤È¡Ê¤³¤Î2ǯ´Ö¤Ï¾åµ­¤Î5ǯ´Ö¤Î¤¦¤Á¤Î1ǯ¤Ë½¼Åö¤Ç¤­¤Þ¤¹¡Ë¡¢À¸¸¡¤Ê¤¤¤·¤Ï¼ê½ÑºàÎÁ¿ÇÃÇ·ï¿ô5000·ï¡¢²ò˶Îã¿ÇÃÇ·ï¿ô40ÂΤʤɤξ¡¢ÉÂÍý³Ø²ñ¤ÎÄê¤á¤ëºÙ¤«¤Ê¸¦½¤¹àÌܤ¬¤¢¤ê¤Þ¤¹¡£ÉÂÍý°å¤Î»Ö˾¼Ô¤Ë¤Ï¤³¤Î¾ò·ï¤òËþ¤¿¤¹¤è¤¦¤Ê¥×¥í¥°¥é¥à¤òÍÑ°Õ¤·¤Æ¡¢½¤Îý¤·¤Æ¤â¤é¤Ã¤Æ¤ª¤ê¤Þ¤¹¡£

¢¥ ¤³¤Î¥Ú¡¼¥¸¤Î¥È¥Ã¥×¤Ø
¶µ°éôÅö
¹ÖµÁ²ÊÌÜ̾¾Î¤ÈÂоݳØǯ

3ǯÀ¸¡¡¥³¡¼¥¹Î×¾²´ðÁðå³ØI¡Ê¥æ¥Ë¥Ã¥È¡§ÉÂÍý³ØÁíÏÀ¡¢¥Ò¥È¤Î»þ´ÖÀ¸Êª³Ø¡¢¼ðáç³Ø­µ¡Ë¡¢±Ñʸ¾¶ÆÉ¡¢¸¦µæ¼¼ÇÛ°
4ǯÀ¸¡¡Î×¾²°å³ØI¡Ê¥æ¥Ë¥Ã¥È¡§¸ÆµÛ´ï¡¢¾Ã²½´É¡¢´ÎÃÀ繡¢¼ðáç³ØII¡Ë
3ǯÀ¸-6ǯÀ¸¡¡°å³ØÁíÏÀ¡ÊCPC¡Ë

¼Â½¬²ÊÌÜ̾¾Î¤ÈÂоݳØǯ

3ǯÀ¸¡¡ÉÂÍý³ØÁíÏÀ¼Â½¬
4ǯÀ¸¡¡ÉÂÍý³Ø³ÆÏÀ¼Â½¬¡¢´ðËÜŪÎ×¾²µ»Ç½¼Â½¬¡¢Î×¾²°å³ØII¡Ê¿·¡Ë
5ǯÀ¸¡¡Î×¾²°å³ØII¡Ê¿·¡Ë

¢¥ ¤³¤Î¥Ú¡¼¥¸¤Î¥È¥Ã¥×¤Ø
Âç³Ø±¡Ã´Åö²ÊÌÜ̾¾Î
Âç³Ø±¡¥¬¥¤¥É¼ø¶ÈºÙÌÜ¡¡¡¡¿ÍÂΡ¦¼Â¸³ÉÂÍý³Ø¡Ê69¥Ú¡¼¥¸¡Ë¤ò¤´»²¾È¤¯¤À¤µ¤¤
¢¥ ¤³¤Î¥Ú¡¼¥¸¤Î¥È¥Ã¥×¤Ø
¼ç¤Ê¸¦µæ¥Æ¡¼¥Þ
¼Â¸³¸¦µæ
  1. ºÙ˦³°¥Þ¥È¥ê¥Ã¥¯¥¹Âå¼Õ¡¦¥×¥í¥Æ¥¢¡¼¥¼¤Ë´Ø¤ï¤ë´ðÁÃŪ¸¦µæ
  2. ¤¬¤óÈù¾®´Ä¶­¤Ë´Ø¤ï¤ë´ðÁÃŪ¸¦µæ
  3. ¿©Æ»¡¢°ß¡¢ÂçIJ³Æ¤¬¤ó¤Î·ÁÂÖŪ²òÀÏ¡¾´â¤ÎȯÀ¸¤È¿ÊŸ¤Ë¤Ä¤¤¤Æ
  4. ÍñÁã¼ðá礪¤è¤Ó»ÒµÜðôÉôÁ£´â¤ÎȯÀ¸µ¡½ø¤ÈÎ×¾²ÉÂÍý³ØŪ¸¦µæ
  5. Á°Î©Á£´â¤ÎÎ×¾²ÉÂÍý³ØŪ¤ª¤è¤Óʬ»ÒÉÂÍý³ØŪ¸¦µæ
  6. ÇÙ´â¤ÎÎ×¾²ÉÂÍý³ØŪ¸¦µæ
  7. ´Î¡´â¡¢ÇÙ´â¤ÎȯÀ¸¤Ë´Ø¤ï¤ëʬ»ÒÉÂÍý³ØŪ¸¦µæ
¢¥ ¤³¤Î¥Ú¡¼¥¸¤Î¥È¥Ã¥×¤Ø
¼ç¤Ê¶ÈÀÓ
  1. Kiyokawa T, Hoang L, Pesci A, Alvarado-Cabrero I, Oliva E, Paek KJ, Soslow RA, Stolnicu S. Claudin-18 as a promising surrogate marker for endocervical gastric-type carcinoma. Am J Surg Pathol 2022; 46(5): 628-36
  2. Joh K, Nakazato T, Hashiguchi A, Shimizu A, Katafuchi R, Okonogi H, Koike K, Hirano K, Tsuboi N, Kawamura T, Yokoo T, Narita I, Suzuki Y. Structural modeling for Oxford histological classifications of immunoglobulin A nephropathy. PloS one 2022; 17(9): e0268731
  3. ±àÉô¾Í»Ò¡¤±­»ô¤Ê¤Ä¤³¡¤²¼Åľ­Ç·¡¥¡ÚÂçIJ¼ðáç¿ÇÎŤκÇÁ°Àþ¡ÛÂçIJ¼ðáçÉÂÍý¿ÇÃǤκÇÁ°Àþ¡¡¥³¥ó¥Ñ¥Ë¥ª¥ó¿ÇÃÇ¡¥°ß¤ÈIJ 57(10): 1312-8
  4. ¸Þ̣߷ °ìδ, ´äÃË ÂÙ, ÃÓü ¾¼·Ä¡¤²¼Åľ­Ç·¡¥¡Ú±ê¾ÉÀ­Ä²¼À´µ¤Ëȼ¤¦Ä²´É´ØÏ¢¤Î¹çÊ»¾É¤ò³Ø¤Ö¡ÛÄÙáçÀ­ÂçIJ±ê¤Ëȼ¤¦dysplasia/ȯ´â¤È¤Ï¤É¤Î¤è¤¦¤Ê¤â¤Î¤«?¡¡ÉÂÍý³ØŪ¤ÊÆÃħ¡¥¾Ã´ÎÆâ²Ê 2022; 12(2); 143-9
  5. Sato S, Kimura T, Onuma H, Egawa S, Shimoda M, Takahashi H. The highest percentage of Gleason Pattern 4 is a predictor in intermediate-risk prostate cancer. BJUI Compass. 2022; 4(2): 234-240
  6. Takei J, Fukasawa N, Tanaka T, Yamamoto Y, Tamura R, Sasaki H, Akasaki Y, Kamata Y, Murahashi M, Shimoda M, Murayama Y. Impact of Neoadjuvant Bevacizumab on Neuroradiographic Response and Histological Findings Related to Tumor Stemness and the Hypoxic Tumor Microenvironment in Glioblastoma: Paired Comparison Between Newly Diagnosed and Recurrent Glioblastomas. Front Oncol. 2022; 12: 898614
  7. Sato S, Kimura T, Onuma H, Egawa S, Shimoda M, Takahashi H. The highest percentage of Gleason Pattern 4 is a predictor in intermediate-risk prostate cancer. BJUI Compass. 2023; 4(2): 234-40
  8. Kiyokawa T. Peritoneal pathology review: Mullerian, mucinous and mesothelial lesions. Surgical pathology clinics. 2022; 15: 259-76
  9. ËÜ´Ö»Ö¸ù¡¤ºä¸ýÎûҡ¤¾ë¸¬Êå¡¥¡Ú¿Õ¡¾É¸õ·²¡ÊÂè3ÈÇ¡Ë-¤½¤Î¾¤Î¿Õ¼À´µ¤ò´Þ¤á¤Æ-[­µ]¡Û»åµåÂμÀ´µ¡¡Â­ºÙ˦Æþ»åµåÂξɡ¥ÆüËÜÎ×¾²Ê̺ý¡Ê¿Õ¡¾É¸õ·²I¡Ë 2022; 98-102
  10. º´Æ£½Ô¡¤Â붶¹À¹¬¡¥Â®Êó²òÀâ!¤³¤³¤¬ÊѤï¤Ã¤¿¡¡¡ÖÁ°Î©Á£´â¼è°·¤¤µ¬Ìó¡¡Âè5ÈǡײþÄû¥Ý¥¤¥ó¥È¡¥ÉÂÍý¤ÈÎס¡2022; 40(9): 910-2
¢¥ ¤³¤Î¥Ú¡¼¥¸¤Î¥È¥Ã¥×¤Ø
¼ç¤Ê¶¥ÁèŪ¸¦µæÈñ

ʸ²Ê¾Ê²Ê¸¦Èñ¡¢³Æ¼ïºâÃĤʤÉ

¢¥ ¤³¤Î¥Ú¡¼¥¸¤Î¥È¥Ã¥×¤Ø

¡¡https://jikei-pathology.jp/

¢¥ ¤³¤Î¥Ú¡¼¥¸¤Î¥È¥Ã¥×¤Ø